Search
Taysha Gene Therapies Inc
TSHAAdd to Watchlist
6.650USD
-0.160-2.35%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.13BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of Taysha Gene Therapies Inc is 8.57, ranking 99 out of 387 in the Biotechnology & Medical Research industry. The average price target is 10.50, with a high of 19.00 and a low of 5.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
13.000
Target Price
+90.90%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Taysha Gene Therapies Inc
TSHA
13
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Taysha Gene Therapies Inc's expected revenue for the next quarter?
Taysha Gene Therapies Inc's expected revenue is 618.18K.
What is Taysha Gene Therapies Inc's price target?
Analysts forecast that Taysha Gene Therapies Inc's price target is USD 10.50, with the highest forecast at USD 19.00 and the lowest forecast at USD 5.00.
How have Taysha Gene Therapies IncTSHA's recent earnings per share performed?
The market expectation was USD -0.12, while Taysha Gene Therapies IncTSHA's earnings per share (EPS) for the previous quarter was USD -0.08. EPS for the next quarter is expected at USD -0.12.
What is the analyst rating for Taysha Gene Therapies Inc?
Based on the ratings of Taysha Gene Therapies Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.